Skip to main content

Table 2 Summary of response rates

From: A retrospective evaluation of activity of gemcitabine/platinum regimens in the treatment of recurrent ovarian cancer

Response Rates Gemcitabine +Cisplatin Gemcitabine + Carboplatin
Overall N = 21 N = 24
Progression #(%) 10 (63) 7(44)
Complete response #(%) 2(13) 3(19)
Partial response #(%) 2(13) 3(19)
Stable disease #(%) 2(13) 3(19)
Discontinued due to toxicity #(%) 5(24) 8(33)
Objective response rate (PR + CR + SD) #(%) 6(38) 9(56)
Mean time to progression (months) [# ± SD (Range)] p = 0.03 7.2 [±2(3.2–9.7)] 5.1 [±1.7(2.3–7.2)]
Response Rates Gemcitabine +Cisplatin Gemcitabine + Carboplatin
Platinum Sensitive N = 10 N = 17
Progression #(%) 6(75) 4(33)
Complete response #(%) 1(13) 3(25)
Partial response #(%) 0(0) 3(25)
Stable disease #(%) 1(13) 2(17)
Discontinued due to toxicity #(%) 2(20) 5(29)
Objective response rate (PR + CR + SD) #(%) p = 0.05 2(25) 8(67)
Mean time to progression (months) [# ± SD (Range)] 7.2 [±2.5(3.2–9.5)] 5.1 [±1.8(2.3–7.2)]
Response Rates Gemcitabine +Cisplatin Gemcitabine + Carboplatin
Platinum Resistant N = 10 N = 7
Progression #(%) 3(43) 3(75)
Complete response #(%) 1(14) 0(0)
Partial response #(%) 2(29) 0(0)
Stable disease #(%) 1(14) 1(25)
Discontinued due to toxicity #(%) 3(30) 3(75)
Objective response rate (PR + CR + SD) #(%) 4(57) 1(25)
Mean time to progression (months) [# ± SD (Range)] 7.2 [±1.6(5.7–9.7)] 5.1 [±1.8(2.5–6.8)]
  1. Abbreviations: SD Standard deviation, PR Partial response, CR Complete response, SD Stable disease